New Portfolio Addition: Arovella Therapeutics

Today we are finally announcing a new investment in the Next Investors portfolio. Arovella Therapeutics (ASX:ALA) is a small ASX biotech going after a unique solution to the scourge of cancer - with cutting edge technology licensed from some of the foremost cancer research institutions - and has attracted big names to the project.

Introducing: Our Biotech Pick of the Year 2021

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

$2.6M Capped eSense-Lab Signs US$600k Revenue Deal

Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.

OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe

OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).

Archer materialises the road to commercialisation

Archer Materials (ASX:AXE) announced the successful and scalable assembly of qubit array components of the 12CQ room-temperature qubit processor.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.